2020-09-08| Asia-PacificCOVID-19

Cooperation of Two Chinese Pharma Launched Massive Clinical Trials Abroad

by Judy Ya-Hsuan Lin
Share To

To defeat the COVID-19 pandemic and protect its workers against potential resurgences, Sinovac Biotech, headquartered in Beijing, China, announced that 90% of its employees and their families (2000-3000 participants) inoculated its experimental coronavirus vaccine CoronaVac voluntarily under China’s emergency program, launched in July. The program was intended for higher risk groups, including medical personnel, workers at food markets, and the transportation and service sectors’ employees. According to the publication last month, the adverse effects of the vaccine candidate were mild with symptoms such as fatigue, fever, and pain, involving 600 participants in a mid-stage trial. However, many factors seemed to impede the commercialization of the CoronaVac and thus China had to fight back with more legitimate data and strategic diplomacy.

Related article: Entering Late into the COVID-19 Vaccine Race, Could this Pharma Duo Measure up to Competition?

Although the safety results demonstrated excellent tolerability of CoronaVac to the sample population, the data could not be utilized as main materials for regulation in judging the viability for commercial use due to the absence of registering the emergency program’s clinical study under clinical trial protocols. To retrieve legit clinical results, Sinovac Biotech and Sinopharm were attempting to make deals on arranging clinical trials outside of China with countries such as Turkey, Bangladesh, Serbia and Pakistan. According to Yun-Tao Zhang, Vice President of Sinopharm, approximately 50,000 individuals from ten countries will be engaged in a Phase 3 trial of CoronaVac and countries, including the United Arab Emirates, Bahrain, Peru, Morocco, Argentina and Jordan have already begun the trials. Besides, Sinopharm has placed an order of 500 million vaccines.

Two New Coronavirus Vaccines Enter Human Trials in China

By Judy Ya-Hsuan Lin



© All rights reserved. Collaborate with us:
Related Post
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top